The FDA has granted approval for the ANDA of Lupin’s Sacubitril and Valsartan Tablets for heart failure patients.

The blood pressure study could help doctors treating people with diabetes to reduce the risk of "major cardiovascular events" ...

The blood pressure study could help doctors treating people with diabetes to reduce the risk of "major cardiovascular events" ...

People with type 2 diabetes had significantly fewer heart attacks, strokes, heart failures, and deaths from cardiovascular ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

Researchers from the UT Southwestern Medical Center have found that lower blood pressure can stop people with type 2 diabetes ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and ...

Supine hypertension in those without seated hypertension is linked to higher risks for adverse cardiovascular events in ...

and a pulmonary arterial systolic pressure of 65 mm Hg (normal, <35). How would you further evaluate and treat this patient? Heart failure with preserved ejection fraction is a heterogeneous syndrome.

there is compelling rationale for extending the preliminary physiologic benefits of sildenafil seen in 'systolic' heart failure to the population with 'diastolic' heart failure. The RELAX trial ...